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The invariant arginine 
within the chromatin-binding motif regulates 
both nucleolar localization and chromatin 
binding of Foamy virus Gag
Joris Paris1†, Joëlle Tobaly‑Tapiero1†, Marie‑Lou Giron1, Julien Burlaud‑Gaillard2,3, Florence Buseyne4,5, 
Philippe Roingeard2,3, Pascale Lesage1, Alessia Zamborlini1,6*‡  and Ali Saïb1*‡
Abstract 
Background: Nuclear localization of Gag is a property shared by many retroviruses and retrotransposons. The impor‑
tance of this stage for retroviral replication is still unknown, but studies on the Rous Sarcoma virus indicate that Gag 
might select the viral RNA genome for packaging in the nucleus. In the case of Foamy viruses, genome encapsidation 
is mediated by Gag C‑terminal domain (CTD), which harbors three clusters of glycine and arginine residues named GR 
boxes (GRI‑III). In this study we investigated how PFV Gag subnuclear distribution might be regulated.
Results: We show that the isolated GRI and GRIII boxes act as nucleolar localization signals. In contrast, both the 
entire Gag CTD and the isolated GRII box, which contains the chromatin‑binding motif, target the nucleolus exclu‑
sively upon mutation of the evolutionary conserved arginine residue at position 540 (R540), which is a key determi‑
nant of FV Gag chromatin tethering. We also provide evidence that Gag localizes in the nucleolus during FV replica‑
tion and uncovered that the viral protein interacts with and is methylated by Protein Arginine Methyltransferase 1 
(PRMT1) in a manner that depends on the R540 residue. Finally, we show that PRMT1 depletion by RNA interference 
induces the concentration of Gag C‑terminus in nucleoli.
Conclusion: Altogether, our findings suggest that methylation by PRMT1 might finely tune the subnuclear distribu‑
tion of Gag depending on the stage of the FV replication cycle. The role of this step for viral replication remains an 
open question.
Keywords: Foamy virus, Gag, Nuclear trafficking, Nucleolus, Chromatin‑binding, Post‑translational modification, 
Methylation, PRMT
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Background
Foamy viruses (FVs), also known as spumaviruses, are 
complex retroviruses that belong to the Spumaretro-
virinae subfamily of the Retroviridae. They are endemic 
among many animal species, particularly non-human 
primates (NHPs) (for a review [1]). The Prototype FV 
(PFV) was isolated from human-derived cell culture and 
later found to be a chimpanzee FV [2]. It is currently 
well established that humans are not natural hosts but 
acquire infection as a consequence of zoonotic transmis-
sion of simian FVs (SFVs) through bites of captive or wild 
NHPs [3, 4]. FV infection is persistent and apparently 
benign [1] and human-to-human transmission has never 
been reported. Like all retroviruses, FVs reverse tran-
scribe their RNA genome (gRNA), which encodes the 
typical gag, pol and env genes, and integrate the result-
ing cDNA into the host cell chromosomes. However, 
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specificities in the replication strategy of FVs set them 
apart from orthoretroviruses. These include the fact that 
reverse transcription occurs during viral particle produc-
tion [5, 6], and that Pol is expressed independently of 
Gag from a specific spliced transcript [7, 8]. The struc-
tural organization and maturation profile of FV Gag are 
also peculiar. FV Gag lacks the major homology region 
(MHR) and the Cys-His zinc-finger motifs that are hall-
marks of orthoretroviral Gag proteins. Moreover, FV Gag 
is not processed into the matrix (MA), capsid (CA) and 
nucleocapsid (NC) mature products like its orthoretro-
viral counterparts, but rather undergoes a single cleav-
age event that removes a 4 kDa C-terminal peptide ([9], 
reviewed in [10]). This feature is shared by the Gag pro-
teins of the Drosophila retrovirus Gypsy [11] and the 
Ty1 retrotransposon of S. cerevisiae [12]. Recent studies 
showed that PFV Gag N-terminal domain (NTD, amino 
acids (aa) 1–180) is entirely unrelated to its orthoretrovi-
ral counterpart [13]. They also confirmed that the NTD, 
which harbors the cytoplasmic targeting and retention 
signal (CTRS) and the self-dimerization domain, plays a 
role similar to orthoretroviral CA in viral capsid assem-
bly [13]. In contrast the central conserved region of PFV 
Gag (aa 300–477), which is involved in the formation of 
higher-order multimers, shares a conformation analo-
gous to that of orthoretroviral CA, suggesting evolution 
from a common ancestral protein [14]. In the absence 
of structural data, functional studies indicate that the 
C-terminal domain (CTD, aa 400–648) of FV Gag plays 
a role related to that of orthoretroviral NC in genome 
packaging [10, 15]. This domain is enriched in glycine 
and arginine residues that in primate FV Gag proteins are 
clustered in three regions named GR boxes (GRI-III) [15]. 
GRI binds nucleic acids in vitro and was proposed to be 
responsible of the incorporation of both the gRNA and 
Pol into virions [16–18]. The GRII box shows the high-
est conservation throughout evolution and is involved 
in the accumulation of PFV Gag in the nucleus [15]. The 
determinant for nuclear localization within GRII maps to 
a 13-aa chromatin binding sequence (CBS, aa 534–546) 
that recognizes the H2A/H2B core histones. This inter-
action tethers the pre-integration complex (PIC) to host 
cell chromatin prior to viral integration [19–21]. The role 
of GRIII in FV replication is enigmatic but likely related 
to that of GRI, since the two motifs can functionally com-
plement each other [22]. Although the GR boxes were ini-
tially viewed as independent entities playing both specific 
and redundant functions, a recent study rather indicates 
that the positively charged residues within the CTD, not 
the GR boxes individually, mediate gRNA packaging and 
Pol encapsidation [23].
During FV replication Gag displays different subcel-
lular localizations, as a result of numerous interactions 
with the intracellular trafficking machinery, which likely 
match its multiple roles throughout the viral life cycle. 
Our previous studies showed that, as a component of 
the incoming PIC, Gag drives the traffic of viral parti-
cles towards the microtubule-organizing center (MTOC) 
where uncoating occurs [24–26]. Upon nuclear envelope 
breakdown, Gag associates with host cell chromosomes 
and critically contributes to the selection of the inte-
gration sites [19–21, 27]. At a later stage, newly synthe-
sized Gag molecules have been shown to oligomerize in 
the nucleus and, next, reach the cytoplasm by engaging 
the CRM1 (Chromosomal Maintenance 1, also known 
as Exportin 1)-dependent pathway through a nuclear 
export signal (NES) [28], as reported for Rous Sarcoma 
Virus (RSV) (see below, [29]). Currently, how newly syn-
thesized Gag crosses the intact nuclear membrane is 
unknown [20].
Evidence that Gag proteins shuttle between the nucleus 
and the cytoplasm has been reported for other retrovi-
ruses, including RSV, feline immunodeficiency virus 
(FIV), Human Immunodeficiency Virus (HIV), mouse 
mammary tumor virus (MMTV), Mazon-Pfizer monkey 
virus (MPMV) and murine leukemia virus (MLV) ([30] 
and references therein), and the Tf1 retrotransposon [31]. 
Gag or the isolated NCs of MMTV, RSV, FIV, HIV and 
MLV have also been detected in the nucleolus ([30] and 
references therein), a distinct subnuclear compartment 
that forms around the gene clusters encoding rRNAs and 
represents the site of ribosomes biogenesis. Although in 
most instances the significance of Gag nucleocytoplas-
mic trafficking for virus replication is elusive, RSV Gag 
was shown to oligomerize in the nucleus, in an RNA- 
and NC-dependent manner [29]. The observation that 
nuclear trafficking of RSV Gag is required for efficient 
genome encapsidation [32, 33] and that binding to a 
synthetic oligonucleotide mimicking the packaging sig-
nal favours the association between Gag and the nuclear 
export factor CRM1 in vitro [34], led to propose a model 
according to which RSV Gag selects the viral gRNA for 
packaging in the nucleus.
To deepen our understanding of the nuclear trafficking 
of PFV Gag, we studied the localization of the C-terminal 
GR boxes and established that the isolated GRI and GRIII 
boxes are nucleolar localization signals (NoLSs). We 
also found that Gag localizes at least temporarily in the 
nucleolus during PFV replication. Next, we investigated 
the mechanisms that regulate this process, and identi-
fied the evolutionary conserved arginine residue at posi-
tion 540 (R540) within the GRII box as a critical factor 
determining whether Gag localizes in the nucleolus or is 
tethered to chromatin. We also established that PFV Gag 
interacts with and is modified by PRMT1 (Protein Argi-
nine Methyltransferase 1) and PRMT5. Interestingly, we 
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found that PFV Gag harboring the R540A substitution is 
unable to interact with PRMT1 and lost the asymmetric 
dimethylarginine (ADMA) mark, while retaining binding 
to and modification by PRMT5. Finally, we observed that 
siRNA-mediated depletion of PRMT1 leads to nucleo-
lar accumulation of the C-terminus of PFV Gag fused to 
GFP. On the basis of these results, we hypothesize that 
PRMT1-mediated methylation, which requires the invar-
iant R540 residue, could regulate the subnuclear distribu-
tion of PFV Gag antagonizing nucleolar accumulation in 
favor of chromosome binding.
Results
The GRI and GRIII boxes of PFV Gag are nucleolar 
localization signals
The GR boxes within PFV Gag CTD are short sequences 
enriched in arginine residues, which is a hallmark of 
NoLSs [35] (Fig. 1a and Additional file 1: S1A). To deter-
mine if these motifs could localize proteins to the nucleo-
lus, we cloned each GR box in frame with the EGFP gene. 
The cellular distribution of the resulting GFP-fusion 
proteins was studied in HeLa cells that were stained 
for nucleolin, one of the most abundant proteins of the 
nucleolus [36]. We found that GFP-GRI was concentrated 
in nucleolin-positive foci, GFP-GRII displayed a diffuse 
nuclear staining, while GFP-GRIII was both enriched in 
nucleolin-positive foci and distributed throughout the 
nucleoplasm and the cytoplasm (Fig. 1b). GFP-GRI stain-
ing also partially overlapped with DsRed fused to the 
NoLS of the HIV Rev protein (DsRed-RevNoLS) (Fig. 1c), 
which localizes in both the Dense Fibrillar Component 
(DFC) and the Granular Component (GC) nucleolar 
compartments where the early events in rRNA transcrip-
tion and processing and maturation of pre-ribosomal 
subunits occur, respectively [37]. In agreement with this 
observation, GFP-GRI co-localized with fibrillarin and 
nucleophosmin/B23, which specifically mark the DFC 
and the GC, respectively (Fig. 1c). Furthermore, an over-
lap between GFP-GRI and the Upstream Binding Factor 
(UBF) located in the Fibrillar Center (FC) was observed 
(Fig.  1c). Ultrastructural analysis by immunoelectron 
microscopy confirmed the presence of GFP-GRI and 
GFP-RevNoLS in the DFC and GC (Additional file 1: Fig 
S1B). We further observed that DsRed-GRI and GFP-
GRIII co-localized when expressed in the same cell, con-
firming that the GRI and the GRIII box target the same 
subnuclear compartment (Additional file 1: Fig. S1C). A 
co-localization was observed between DsRed-PFV-GRI 
Fig. 1 GRI and GRIII boxes of PFV Gag are Nucleolar Localization Signals. a Scheme of PFV Gag protein where the primary protease‑cleavage site at 
residue 621 is indicated by a dotted line. Some characterized motifs are shown. CTRS: cytoplasmic targeting and retention signal (aa 43–60); NES: 
nuclear export signal (aa 95–112); dim: dimerization domain (aa 130–160); GRI, GRII and GRIII: glycine‑arginine rich box I (aa 485–511), II (aa 534–557) 
and III (aa 586–618); CBM, chromatin‑binding motif (aa 536–544). b The subcellular localization of GRI, GRII,  GRIIR540A or GRIII expressed as GFP‑fusion 
proteins in fixed HeLa cells was analyzed 24 h post‑transfection by immunofluorescence and confocal microscopy. Nucleoli were immune‑stained 
with an anti‑nucleolin antibody (ab 22758, Abcam, 1:800) and nuclei were stained with DAPI (blue). c The localization of GFP‑GRI expressed in HeLa 
cells relative to the NoLS of HIV‑1 Rev protein (aa 35–51) in fusion with DsRed or specific markers of the nucleolar subcompartments was studied 
as in B. Cells were stained with antibodies against fibrillarin (c13c3, Cell signaling, 1:200), B23 (sc6013_R, Santa Cruz, 1:200) or UBF (H300, Santa Cruz, 
1:200) to visualize the dense fibrillar component (DFC), the granular component (GC) and the fibrillar center (FC), respectively. The right column 
(zoom × 16) corresponds to the enlarged images from the boxed areas. Scale bar represents 10 µm
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and GFP fused to either the GRI or the GRIII box of the 
Equine Foamy virus (EFV), the most distantly related 
FV (Additional file 1: Fig. S1C). Altogether these results 
indicate that the GRI and GRIII boxes of FV Gag proteins 
are NoLSs able to induce the nucleolar localization of a 
heterologous protein, and that this function is conserved 
among primate and non-primate FVs.
FV Gag transits through the nucleolus during viral 
replication
Having shown that GRI and GRIII are NoLSs, we asked 
whether FV Gag transits through the nucleolus during 
PFV life cycle. The fact that PFV Gag has never been 
detected in the nucleolus of infected cells suggests that 
either this process is highly dynamic and/or that only a 
small fraction of the protein resides in the nucleolus at 
steady state. To address this question, we adopted a “cap-
ture” assay similar to that used to demonstrate nucleolar 
trafficking of HIV Rev [38]. To this end, we established 
U373MG cells stably expressing a chimeric protein 
named Gag-TRAP-GFP, which consists of the N-ter-
minal region of Gag (aa 1–200) including the dimeriza-
tion domain [13, 39], fused with the NoLS of HIV Rev 
and GFP (Fig.  2a). We reasoned that if FV Gag tran-
sits through the nucleolus, it would interact with Gag-
TRAP-GFP and be consequently retained at this site. As 
expected, Gag-TRAP-GFP accumulates in the nucleolus 
(Fig. 2b). We also confirmed that Gag-TRAP-GFP co-pre-
cipitates with full-length PFV Gag (Additional file 2: Fig. 
S2). Next, U373MG cells stably expressing Gag-TRAP-
GFP, or the appropriate controls (GFP,  Gag1-200-GFP or 
RevNoLS-GFP), were infected with PFV. Seventy-two 
hours later, Gag distribution was analyzed by immuno-
fluorescence and confocal microscopy with an antibody 
directed against the C-terminal half of Gag. In control 
cells, Gag (red staining) localized in the cytoplasm and/
or in the nucleus, but was not detected in the nucleo-
lus (Fig.  2b), while in Gag-TRAP-GFP-expressing cells, 
Gag was diffused in the nucleoplasm and co-localized 
with the chimeric protein in the nucleolus. The infec-
tivity of viruses released in the cell culture supernatant 
was quantified in parallel using FAG-indicator cells [39]. 
Viruses produced from cells expressing RevNoLS-GFP 
or  Gag1-200-GFP were not significantly less infectious 
compared to those produced from GFP-expressing cells, 
used for normalization (96% ± 14 and 91% ± 3 compared 
to 100 ± 15, respectively) (Fig.  2c). Expression of Gag-
TRAP-GFP resulted in a reduction of infectivity of about 
25% (75% ± 13 and 73% ± 11 for independent duplicate 
samples) (Fig.  2c). Statistical analysis shows that such 
decrease in infectivity is statistically significant when 
compared to the GFP, but not to the  Gag1-200-GFP, sam-
ple (Fig. 2c).
Since we could not exclude that the interaction 
between Gag and Gag-TRAP-GFP occurs outside the 
nucleolus and that the Rev NoLS within the chimeric 
protein subsequently targets the complex to this subcel-
lular site, we analyzed Gag localization in PFV-infected 
U937MG cells treated with leptomycine B (LMB), a spe-
cific inhibitor of CRM1-mediated nuclear export, and/or 
exposed to hypoxia, a setting that was previously shown 
to slow down protein trafficking [40]. Under these condi-
tions, Gag (green staining) co-localized with nucleolin in 
about 3–10% of PFV-infected cells (Fig.  2d). Altogether 
these results indicate that Gag transits through the nucle-
olus during PFV replication.
The evolutionary conserved R540 residue is critical 
for both nucleolar localization and chromosome tethering 
of PFV Gag
Our observations showing that Gag localizes at least tem-
porarily in the nucleolus during PFV infection, raise the 
question of how this process is regulated. Given that GRI 
and GRIII, but not GRII, are NoLSs (Fig. 1b), we decided 
first to study the subcellular distribution of GFP fused 
to PFV Gag CTD encompassing the three GR boxes (aa 
477–625). The resulting GFP-GRs fusion protein was dif-
fused throughout the nucleoplasm and excluded from 
the nucleoli (Fig.  3a, left panel), a localization pattern 
reminiscent of that of GFP-GRII (Fig. 1b). This observa-
tion suggested that the GRII box might antagonize the 
nucleolar-targeting function of GRI and/or GRIII. In sup-
port of this hypothesis, deletion of either the entire GRII 
box or the chromatin-binding motif (CBM, aa 536–544) 
in the context of GFP-GRs induced an accumulation of 
the corresponding mutants in the nucleolus (Fig. 3a, left 
panel). To map further the determinants of GRII that 
influence nucleolar-targeting, we aligned the sequences 
of the GRII box from several FV isolates and found that 
PFV CBM residues Y537 and R540 are strictly conserved, 
while R542 is only present in Gag from some primate 
FVs, EFV and in CoeEFV, an endogenous foamy virus-
like element in the Coelacanth genome [41] (Table  1). 
Each of these residues was mutated within the GFP-GRs 
construct to address their contribution to nucleolar tar-
geting. GFP-GRsR542A displayed a WT distribution in 
HeLa cells (Fig. 3a, left panel). GFP-GRsY537A localized 
in the nucleoplasm in most instances, but was detected 
also in the nucleolus in about a third of the transfected 
cells (Fig.  3a, left panel). In contrast, GFP-GRs where 
R540 is mutated to A, K or F accumulated in nucleoli 
in the whole population of transfected cells (Fig. 3a, left 
panel and Fig.  3b). These observations are consistent 
with the finding that GFP-GRII harboring the R540A 
mutation co-localizes with nucleolin (Fig. 1b). Finally, we 
found that GFP fused to the C-terminal region of EFV 
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Gag (EFV GFP-GRs) was distributed in the nucleoplasm 
(Additional file 1: Fig. S1D). Upon alanine substitution of 
R472, which is equivalent of PFV Gag R540, EFV GFP-
GRs accumulated in the nucleolus (Additional file 1: Fig. 
S1D). 
We next studied the influence of R540 on full-length 
PFV Gag localization. PFV Gag expressed as GFP-
fusion protein in HeLa cells was predominantly diffused 
in the cytoplasm of interphasic cells, and was excluded 
from the nucleolus (Fig.  3c, left panel). Upon deletion 
of the CBM or mutation of R540 to A, GFP-Gag accu-
mulated in the nucleolus in a fraction of transfected 
HeLa cells (about 7 and 10%, respectively) (Fig. 3c, left 
panel). These results contrasted with the finding that 
GFP-GRsR540A was detected in the nucleolus in all 
the transfected cells (Fig.  3a, left panel). We hypoth-
esized that this discrepancy might result at least in 
part from the presence of N-terminal sequences within 
Gag favoring its accumulation in the cytoplasm and/
or antagonizing its nuclear/nucleolar localization. To 
Fig. 2 Gag transits through the nucleolus during PFV infection. a Schematic representation of the experimental strategy used to study PFV Gag 
trafficking through the nucleolus in U373MG cells stably expressing the Gag‑TRAP‑GFP protein  (Gag1‑200‑RevNoLS‑GFP). b U373MG cell lines 
stably expressing GFP, RevNoLS‑GFP,  Gag1‑200‑GFP or Gag‑TRAP‑GFP were infected with replication competent PFV. After 72 h, the localization of 
Gag (red staining) was analyzed in fixed cells using a rabbit polyclonal antibody specific of the C‑terminal half of Gag (aa 382–648). Images were 
acquired as described in Fig. 1b. c Virions released in the supernatant 72 h after infection were titrated on FAG indicator cells and the percentage 
of infected (GFP‑positive) cells was measured by flow cytometry. The infectivity of virions produced by GFP‑expressing U373MG cells was used for 
normalization. Results from 4 independent experiments performed in three replicates each are expressed as the mean ± SD (standard deviation). 
Significance compared to GFP was calculated using a one‑way ANOVA statistical test with a Bonferroni Multiple comparison post‑test (*p < 0.05; 
**p < 0.01). d The subcellular localization of Gag was studied in PFV infected U373MG cells treated or not with LMB (10 nM, 6 h) and/or exposed 
to hypoxia (2%  O2, 4 h). At 48 h post‑infection, cells were fixed and stained with a mouse polyclonal antibody against full‑length Gag (green) and 
rabbit polyclonal anti‑nucleolin antibody (ab 22,758, Abcam, 1:800). Two hundreds cells were counted for each sample. Nuclei were stained with 
DAPI (blue). Images were acquired as described in Fig. 1b. Scale bar represents 10 µm
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address this point, we mutated three well-characterized 
functional domains in GFP-Gag or GFP-GagR540A, 
namely the CTRS (mutation R50A) [42], the NES 
(mutation G110  V) [28] and the dimerization domain 
(Δdim, deletion of aa 130–160) [39] (Fig. 1a). In agree-
ment with these published studies, GFP-Gag bearing 
the R50A or G110V or Δdim mutation accumulated 
in the nucleus (Fig.  3c, left panel). When any of these 
mutations was combined with the R540A substitution, 
the resulting GFP-Gag variants were distributed in the 
cytoplasm and the nucleoplasm and also accumulated 
in the nucleolus, to a variable extent (Fig. 3c, left panel).
Having previously shown that deletion of the CBM 
impairs FV Gag binding to mitotic chromosomes [19], we 
also addressed the involvement of the conserved residues 
Fig. 3 The invariant R540 residue in PFV Gag regulates nucleolar localization and binding to mitotic chromosomes. Living HeLa cells expressing the 
indicated GFP‑GRs (a) or GFP‑Gag (c) constructs and stained with Hoechst 33342 were observed on a confocal microscope 24 h after transfection 
(left panels). Merged images correspond to GFP, nucleic acid staining and differential interference contrast to visualize the cell shape. The “% 
nucleolar” column indicates the percentage of transfected cells displaying GFP staining in the nucleolus (−, < 1%; +, 1–25%; ++, 26–50%; +++, 
51–75%; ++++ , 76–100%). To study the interaction of GFP‑fusion proteins with chromatin (right panels), cells ectopically expressing indicated 
proteins were arrested in metaphase by treatment with colcemid (0.1 µg/mL, 2 h) and chromosome spreads counterstained with DAPI. Images 
were acquired as described in Fig. 1b. The chromatin binding column indicates whether the GFP‑fusion protein was exclusively localized onto 
chromosomes (++), both on chromosomes and throughout the cell (+), or was distributed throughout the cell and did not associate with 
chromosomes (−). Representative images from two independent experiments are shown. Between 100 and 120 cells were analyzed for each 
condition. Scale bars represent 10 µm. b HeLa cells expressing the indicated GFP‑GRs were stained with DAPI. Images were acquired as described in 
Fig. 1b. Scale bars represent 10 µm
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within the GRII box in the interaction of FV Gag with 
chromatin. Gag variants where Y537 or R542 are changed 
to A retained the ability to interact with mitotic chromo-
somes (Fig. 3a, c, right panel). Notably, mutation of R540 
to A was sufficient to abolish binding of either the CTD 
or full length Gag expressed as GFP-fusion proteins to 
chromatin (Fig.  3a, c, right panel). The results obtained 
in metaphase spreads were confirmed by the observation 
of fixed cells expressing GFP-GRs R540A that undergo 
mitosis, as judged by DNA staining (Fig.  3b). Similarly, 
we never observed an association between mitotic chro-
mosomes and GFP-GRs bearing the R540F mutation, 
which mimics constitutive methylation (Fig. 3b). Finally, 
we found that GFP-GRs carrying the R540  K change 
painted the chromosomes of mitotic cells (Fig. 3b), indi-
cating that a positive charge at position 540 is sufficient 
to ensure interaction of Gag with the H2A/H2B core his-
tones [19, 21]. Altogether our findings indicate that the 
phylogenetically conserved R540 residue of PFV Gag is 
critical to regulate the subnuclear distribution of the pro-
tein: i.e. its nucleolar localization versus mitotic chromo-
somes binding.
R540 is required for both PRMT1 binding and ADMA 
modification of PFV Gag
To further understand the regulation of PFV Gag subnu-
clear distribution by R540, we asked whether this residue 
might be targeted by post-translational modifications, 
particularly methylation. To address this point, we tested 
whether Gag could interact with any of the nine Protein 
Arginine Methyltransferases identified in human cells 
(PRMT1 to PRMT9) [43]. We performed co-immunopre-
cipitation assays on 293T cells expressing WT Gag and 
each PRMT protein fused to GFP and observed that Gag 
binds to GFP-PRMT1 and GFP-PRMT5, but no other 
GFP-PRMTs (Additional file  3: Fig. S3A). These inter-
actions were confirmed by performing the reciprocal 
experiment (Fig. 4a and Additional file 3: S3B). Interest-
ingly, we found that the R540A Gag mutant lost the abil-
ity to interact with GFP-PRMT1 (Fig.  4a, IP GFP), but 
still co-precipitated with GFP-PRMT5 (Additional file 3: 
Fig. S3B, IP GFP). The R540A change also abolished the 
interaction between Gag CTD (comprising the three GR 
boxes) and endogenous PRMT1 (Fig.  4b, IP PRMT1). 
Therefore, R540 is specifically required for Gag binding 
to PRMT1. It is worth to mention that Gag CTD bear-
ing the R540A substitution is unable to interact with the 
H2A histone (Fig.  4b, IP HA), which likely explains the 
impaired binding to mitotic chromosomes (Fig. 3).
PRMT1 is the primary methyltransferase that depos-
its the asymmetric dimethylarginine (ADMA) mark, 
whereas PRMT5 performs the symmetric dimethylargi-
nine (SDMA) modification. In GFP-PRMT1-expressing 
cells WT Gag, but not the R540A mutant, can be precipi-
tated with an antibody specific for the ADMA modifica-
tion (Fig. 4a, IP ADMA). Similarly, WTHA-GRs, but not 
the R540A mutant, was enriched on beads coated with 
the anti-ADMA antibody (Fig. 4b). In contrast, both WT 
Gag and the R540A mutant co-precipitated with an anti-
SDMA antibody, when expressed together with GFP-
PRMT5 (Additional file 3: Fig. S3B).
Since mutation of R540 also leads to the accumula-
tion of Gag in nucleoli, we finally asked whether PRMT1 
might influence the subcellular distribution of the viral 
protein. To this purpose, we studied the localization 
of GFP-GRs in HeLa cells previously transfected with 
siRNA targeting PRMT1 or the appropriate scram-
bled control. As shown in Fig.  4c, GFP-GRs is distrib-
uted throughout the nucleoplasm of control cells, while 
accumulates in nucleoli upon siRNA-mediated knock-
down of PRMT1. Altogether these results indicate that 
PRMT1-dependent methylation of PFV Gag C-terminal 
region requires the invariant R540 residue and is neces-
sary to prevent Gag accumulation in nucleoli.
Discussion
It is well established that incoming FV Gag tethers the 
PIC to host cell chromatin contributing to integration 
site selection [19–21]. We also showed that PFV Gag 
harbors a NES, which integrity is required for the com-
pletion of the late stages of viral replication [28]. These 
observations suggest that Gag transits through the 
nucleus at a step following its translation although the 
mechanisms underlying its ability to cross the nuclear 
membrane are still unclear [20]. To get further insights 
in the role of Gag nuclear trafficking for FV replication, 
we investigated the localization of the C-terminal GR 
boxes and found that GRI and GRIII act as NoLSs able 
Table 1 Sequence alignment of Gag CBM from different FV strains. 
Residues that are conserved in > 50 and 100% of the sequences are 
colored blue and red, respectively. The alignment was obtained 
using ESPript (http://espri pt.ibcp.fr) [58]
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to target a heterologous protein (GFP) to the nucleolus. 
This observation underscores once more the functional 
link between these two motifs [22]. We also provide evi-
dence that PFV Gag accumulates to nucleoli in a context 
of infection using two complementary approaches. First, 
we demonstrated that Gag binds to and, at least partially, 
colocalizes with a Gag-TRAP-GFP decoy constitutively 
localized in the nucleolus of PFV-infected cells. Second, 
we visualized Gag in the nucleolus of PFV-infected cells 
exposed to conditions that slow down protein trafficking 
(hypoxia and/or LMB treatment), indicating that nucleo-
lar accumulation occurs during the viral cycle and is not 
a mere artifact of Gag-TRAP-GFP expression. Our find-
ings complement previous reports that Gag and/or the 
isolated NC proteins from several retroviruses display 
nuclear/nucleolar distribution, when expressed either as 
individual proteins or during viral infection (reviewed in 
[30]). The importance of this nuclear/nucleolar stage for 
retroviral replication is still unknown. Notably, the obser-
vation that many proteins of RNA viruses involved in 
genome packaging and viral particle assembly localize to 
nucleoli [44, 45] suggests that these nuclear bodies could 
be sites where viral ribonucleoprotein complexes form to 
facilitate viral RNA export and packaging [46].
Another major finding of our work is that neither full-
length Gag nor an N-terminal truncation mutant encom-
passing the three GR boxes accumulates in nucleoli 
unless the entire GRII box or the CBS is deleted, leading 
us to assume that this region might hold determinant(s) 
antagonizing nucleolar targeting. We mapped this deter-
minant to the invariant R540 residue, which mutation 
is sufficient to induce nucleolar targeting of the isolated 
GRII box or Gag CTD. Of note, localization of full-length 
Gag harboring the R540A mutation in nucleoli required 
concomitant inactivation of N-terminal motifs such as 
the CTRS, the NES or the dimerization domain, condi-
tions that favor nuclear accumulation of the  viral pro-
tein. Consistent with this observation, Müllers et al. [20] 
reported that PFV Gag displays nucleolar staining when 
fused to a heterologous NLS and upon simultaneous 
deletion of the GRII box. Similarly, Lochmann et al. [46] 
described nucleolar localization of RSV Gag after having 
enhanced its concentration in the nucleus by inhibition 
of CRM1-dependent nuclear export or mutation of its 
NES.
Having previously shown that the CBM mediates teth-
ering of PFV Gag to chromatin [19], we assessed the 
implication of R540 in this process. Our data show that 
substitution of R540 to A prevents Gag from binding to 
mitotic chromosomes and interacting with the H2A his-
tone. This finding is in agreement with the recent results 
of Lesbats et al. [21] demonstrating that R540 acts as an 
anchor motif interacting with the acidic patch on the 
surface of the H2A/H2B heterodimer. The role of R540 
in modulating chromatin binding is further supported 
by the observation that insertion of the WT chromatin-
binding sequence (CBS, aa 534–546) of PFV Gag, but not 
the corresponding R540A mutant, restores the interac-
tion between a mutant version of MLV p12 and mitotic 
chromosomes [47]. Notably, we found that Gag CTD 
bearing the R540 K mutation associates to chromatin in 
Fig. 4 PRMT‑1 binds to and methylates PFV Gag in a manner that 
depends on R540. a Following lysis, cells expressing PFV Gag WT 
or R450A mutant and GFP‑PRMT1 were incubated with protein A 
beads coated with either an anti‑GFP (cat.11 814 460 001, Roche, 
1:100) or an anti‑ADMA (ab5394 (7E6), Abcam,1:100) antibody. Input 
and immunoprecipitated proteins were separated by SDS‑PAGE 
and visualized by Western blotting with anti‑GFP (cat.11 814 460 
001, Roche, 1:1000) or rabbit polyclonal anti‑PFV antibodies. b 
Lysates from cells expressing HA‑tagged GRs or GRs‑R540A were 
immunoprecipitated with an antibody directed against PRMT1 (Cat 
A300‑722A, Bethyl Laboratories (Euromedex), 1:100), the ADMA 
modification (ab5394 (7E6), Abcam, 1:100), or the HA epitope (H11, 
Covance, 1:100). Input and bound proteins were analyzed as in A. c 
HeLa cells were transfected with siRNA targeting PRMT1 or scrambled 
control (scr) and, two days later, with GFP‑GRs expression plasmid. 
After 24 h, cells were processed as indicated in Fig. 1b. Images are 
representative of two independent experiments. The numbers 
indicate the percentage of GFP‑positive cells with significant 
nucleolar accumulation of 100 counted cells. Scale bar represents 
10 µm
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cells undergoing unperturbed mitosis, indicating that a 
positive charge at position 540 is necessary and sufficient 
to ensure tethering of PFV Gag on chromatin, but not to 
antagonize nucleolar accumulation.
Finally we set to investigate how R540 regulates the sub-
nuclear localization of PFV Gag. Post-translational modi-
fication of R by methylation has been shown to modulate 
the function and/or localization of several viral proteins. 
Studies on HIV NC revealed that mutation of R residues 
within the NoLSs, which are targeted by PRMT6-medi-
ated methylation, impairs both nucleolar localization [46] 
and reverse transcription initiation [48]. Methylation is 
also proposed to control both the nucleolar distribution 
and the transactivation activity of the HIV Tat protein 
[49, 50]. In the case of HIV Rev mutation of methylated 
R residues or expression of catalytically inactive PRMT6 
diminishes both binding to and nuclear export of RRE-
containing transcripts [51]. Least but not last, methylation 
of R residues influences histone binding of KSHV (Kaposi 
Sarcoma-associated Herpesvirus) LANA (Latency-asso-
ciated Nuclear Antigen) protein [52]. Based on these 
reports, we asked whether PFV Gag is methylated and 
whether this post-translational modification might influ-
ence its subnuclear distribution. In our work we show for 
the first time that PFV Gag interacts with and is methyl-
ated by both PRMT1 and PRMT5. We also established 
that Gag R540A mutant retains the ability to interact 
with PRMT5 and, surprisingly, displays enhanced SDMA 
modification compared to WT Gag. Why mutation of the 
R540 residue would facilitate deposition of SDMA marks 
by PRMT5 and at which sites this modification occurs are 
currently unanswered questions. Importantly, substitu-
tion of R540 with A abolished both Gag association with, 
and modification by, PRMT1. In addition, PFV Gag C-ter-
minus fused to GFP (GFP-GRs) is enriched in nucleoli 
when PRMT1 expression is reduced by RNA interference, 
mimicking the phenotype of the R540 mutation. These 
data are consistent with a model according to which 
PRMT1-mediated modification of PFV Gag antagonize 
its nucleolar accumulation. Although we do not provide 
direct evidence of PRMT1-mediated methylation of R540, 
it is tempting to speculate that reversible modification of 
this amino acid might contribute to finely tune the dis-
tinct functions of Gag at different stages of the replication 
cycle. Nevertheless, finding that Gag mutants where R540 
is mutated to A or F, which mimics constitutive methyla-
tion [53, 54], have a similar phenotype argues that meth-
ylation at this site is neither required for localization in 
nucleoli nor for tethering to chromatin. Another possibil-
ity is that PRMT1 controls Gag subnuclear localization by 
mediating ADMA modification of other residues within 
its R-rich C-terminal region, which await identification. 
PFV Gag was already known to be phosphorylated on 
multiple sites [5, 9]. Recent studies established that phos-
phorylation of T225 occurs exclusively in virions and pro-
pose that this modification is required for the interaction 
between PFV Gag and Polo-like kinases, ultimately lead-
ing to efficient integration [55].
When we assessed the impact of nucleolar retention of 
Gag on PFV replication we found that virions produced 
from Gag-TRAP-GFP-expressing cells display only a mod-
erate decrease of infectivity, which is not statistically sig-
nificant as compared to the infectivity of virions released 
from cells expressing  Gag1-200-GFP, leaving the question of 
the role of PRMT1-dependent methylation and/or nucleo-
lar accumulation of Gag during PFV replication open for 
further investigations. Given that a virus harboring the 
R540Q mutation within the CBM has an altered integra-
tion profile [21], it would also be interesting to address the 
role of Gag methylation for integration site selection.
Conclusion
In closing, our work underscores that Gag localizes in 
the nucleolus during PFV replication. This step is likely 
regulated by PRMT1-mediated methylation of Gag that 
depends on the invariant R540  residue. Further studies 
will be required to define the functional significance of 
the nucleolar step for FV replication as well as the conse-
quences of PFV Gag methylation in regard to the regula-
tion of its complex nuclear transport and integration site 
selection.
Methods
Cells and culture conditions
HeLa, 293T and U373MG cells were cultured in DMEM 
supplemented with 10% Fetal Calf serum (FBS). BHK-
U3GFP indicator FAG (Fluorescence Activated GFP) cells 
were cultured in DMEM supplemented with 5% FBS and 
500 µg/mL G418 (Gibco). Leptomycin B (LMB) (Sigma) 
was added to culture medium to a final concentration of 
10 nM for 4 h. Hypoxic conditions (2%  O2, 5%CO2 and 
93%  N2) were induced by a continuous flow of nitrogen 
using a Forma Series II Water Jacket CO2 incubator 
(model: 3131; Thermo Scientific).
Plasmid constructions
Fusion of individual GR boxes (GRI: aa 485–511, GRII: 
aa 534-557, GRIII: aa 586–618) or RevNoLS (aa 35–51) 
to GFP or RFP was obtained by inserting annealed com-
plementary oligonucleotides of appropriate sequence into 
pEGFP-C1 or pDsRed-C1. GFP-GRs (GRs: aa 477–625) 
and GFP-Gag were constructed by insertion of PCR 
products obtained using the pcziGag as template, into 
pEGFP-C1 (Clontech) between HindIII and BamHI sites. 
HA-GRs expression plasmids were generated by replacing 
GFP by the HA sequence. pHFVGag∆131-162 [39] served as 
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template to generate GFP-Gag∆dim (deletion of PFV Gag 
aa 130–160). Mutants were generated using QuickChange 
site-directed mutagenesis Kit according to the manufac-
turer’s specifications (Stratagene). Fragments spanning 
 Gag1-200, RevNoLS or  Gag1-200 fused to RevNoLS, were 
inserted into pEGFP-N1, and the resulting plasmids were 
used as template to amplify the coding sequences to be 
inserted in pMSCVneo at the EcoRI and HpaI sites. Plas-
mids encoding GFP-tagged human PRMTs proteins were 
kindly provided by Mark Bedford [56].
Establishment of cell lines stably expressing Gag‑TRAP‑GFP
U373MG stable cell lines were established using the 
Murine Stem Cell Virus (MSCV)-based retroviral vector 
system. Recombinant retroviral vectors were generated 
by transfection of 293T cells with the pMSCV-neo vec-
tor encoding  Gag1-200-RevNoLS-GFP (Gag-TRAP-GFP), 
 Gag1-200-GFP, RevNoLS-GFP or GFP, and the packag-
ing plasmids expressing MLV Gag-Pol and the Vesicular 
Stomatitis Virus envelope G glycoprotein (VSV-G) using 
the calcium phosphate precipitation method. Cell-free 
supernatants were collected 48  h post-transfection and 
used to transduce U373MG cells. GFP expression was 
analyzed 48 h post-transduction by flow cytometry. After 
cell sorting, GFP-positive cells were propagated in cul-
ture medium supplemented with G418 (500 µg/mL).
Immunocytochemistry
Indirect immunofluorescence imaging on fixed-cells or 
mitotic chromosome spreads was described elsewhere 
[19]. In brief, samples were incubated with the appropri-
ate primary antibodies (4 °C, overnight) and fluorescent-
labeled secondary antibody (30 min, room temperature). 
Nuclei were stained with 4,6-diamidino-2-phenylindole 
(DAPI). Images were acquired with a laser-scanning con-
focal microscope (LSM510  Meta; Carl Zeiss) equipped 
with an Axiovert 200 M inverted microscope, using a 
Plan Apo 63_/1.4-N oil immersion objective.
Co‑immunoprecipitation assay and Western blotting
Cell pellets were lysed in 0.4 M NaCl, 1 mM  MgCl2, 10% 
sucrose, 0.5 mM DTT, 10 mM PIPES pH 6.8, 0.5% NP-40 
supplemented with Protease Inhibitor Cocktail (Roche) 
(30 min on ice), and subsequently centrifuged (12,000g, 
5  min at 4  °C). Immunoprecipitation and Western-blot 
were performed as previously described [28].
Immuno‑electron microscopy
Transfected 293T cells were prepared as described 
[57]. After extensive washing, the grids were incu-
bated with an anti-GFP monoclonal antibody (90 min, 
RT), followed by an anti-rabbit antibody conjugated to 
15 nm-gold particles (British Biocell International, Car-
diff, UK) (90 min, RT). Ultrathin sections were stained 
with 5% uranyl acetate 5% lead citrate, placed on EM 
grids coated with collodion membrane and observed 
with a Jeol 1010 transmission electron microscope 
(Tokyo, Japan).
RNA interference
HeLa Cells were transiently transfected with ON-TAR-
GETplus Human SMARTpool siRNA targeting PRMT-1 
(Dharmacon #3276) or the scrambled control (10 nM) 
using the Lipofectamine RNAiMax reagent according 
to the manufacturer’s instructions (Life Technologies). 
After 48  h, cells were transfected with the GFP-GRs 
expressor and, following further 24 h incubation, were 
fixed and analyzed by confocal microscopy.
Statistic testing
Graphical representation and statistical analyses were 
performed using the GraphPad Prism software (Graph-
Pad Software, San Diego, CA, USA). Differences were 
tested for statistical significance using ne-way ANOVA 
statistical test with a Bonferroni Multiple comparison 
post-test.
Additional files
Additional file 1: Figure S1. Nucleolar targeting is a conserved feature 
of EFV GRI and GRIII boxes and is antagonized by R472 within GRII. A) 
Amino acid sequences of the GR boxes of PFV and EFV and the NoLS of 
HIV‑1 Rev protein (aa 35–51). B) Electron microscopy images of HeLa cells 
expressing GFP, GFP‑GRI or GFP‑RevNoLS and stained with an anti‑GFP 
antibody (ab6556, Abcam, 1:200) and a secondary antibody coupled to 
15 nm gold particles (goat anti‑rabbit 15 nm Gold, BBI International, 1: 60). 
C) PFV GRI fused to DsRed and PFV GRIII, EFV GRI (aa 395–427) or GRIII (aa 
492–524) fused to GFP were expressed in HeLa cells. Their localization was 
analyzed 24 h later as described in Fig. 1b. Nuclei are stained with DAPI. 
D) The C‑terminal region (GRs) of EFV Gag fused to GFP and bearing the 
R472A mutation or not, was expressed in HeLa cells, and its localization 
was studied as described in Fig. 1b. Nuclei are stained with DAPI. Scale bar 
represents 10 µm.
Additional file 2: Figure S2. Gag‑TRAP‑GFP interacts with PFV Gag. 
Lysates of 293T cells ectopically expressing PFV Gag and Gag‑TRAP‑GFP 
construct  (Gag1‑200‑RevNoLS‑GFP) or the corresponding controls (GFP, 
 Gag1‑200‑GFP or RevNoLS‑GFP) were immunoprecipitated on protein 
A beads coated with an anti‑GFP antibody (cat.11 814 460 001, Roche, 
1:100). Input and bound proteins were analyzed as in Fig. 4a.
Additional file 3: Figure S3. Both WT and R540A mutant Gag bind to 
PRMT5. A) Lysates from 293T cells expressing PFV Gag and each human 
PRMT variant in fusion with GFP were immunoprecipitated with protein 
A beads coated with anti‑PFV antibodies. Input and bound proteins 
were analyzed as in Fig. 4a. B) Cells expressing WT or R450A mutant PFV 
Gag and GFP‑PRMT5 were lysed and incubated with beads coated with 
anti‑GFP (cat.11 814 460 001, Roche, 1:100) or anti‑SDMA (SYM10, 07‑412, 
Millipore, 1:100) antibodies. Input and immunoprecipitated proteins were 
treated as in Fig. 4a.
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